Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women.
One hundred healthy postmenopausal women were randomly assigned to receive 17β-E2 1 mg/drospirenone 2 mg or 17β-E2 1 mg/norethisterone acetate 0.5 mg for 6 months, and circulating soluble Fas, soluble Fas ligand, and cytochrome c were measured at baseline and at 6 months in 87 women who completed the study. Although cytochrome c levels were undetectable, circulating soluble Fas/soluble Fas ligand ratio decreased in both groups, suggesting a decrease in ligand-mediated apoptosis.
Karaflou
Maria
M
Second Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece. mariakaraflou@yahoo.co.uk
Kaparos
George
G
Rizos
Demetrios
D
Creatsa
Maria
M
Christodoulakos
George
G
Lambrinoudaki
Irene
I
D000736:Androstenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D006262:Health; D006801:Humans; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D000077563:Norethindrone Acetate; D017698:Postmenopause / Q000097:blood / Q000187:drug effects* / Q000502:physiology; D011372:Progestins / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*
D000736:Androstenes; D051017:Apoptosis Regulatory Proteins; D015415:Biomarkers; D011372:Progestins; D004958:Estradiol; D000077563:Norethindrone Acetate; C035144:drospirenone; D009640:Norethindrone